Compare Stryker Corporation (SYK) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs Wells Fargo & Co — how do they compare? Stryker Corporation trades at $276.85 (market cap $106.24B), while Wells Fargo & Co trades at $82 (market cap $248.06B). The key difference: Wells Fargo & Co is far larger — about 2.3× Stryker Corporation's market cap, and Wells Fargo & Co pays the higher dividend (2.44%). Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 20 Days and Wells Fargo & Co for 87 Days on average.
| SYK | WFC | |
|---|---|---|
Market Cap | $106.24B | $248.06B |
Volume | 2,982,001 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $388.35 | $96.40 |
52-Week Low | $269.75 | $73.42 |
Typical Hold Time | 20 Days | 87 Days |
Enterprise Value | $117.70B | $503.91B |
Dividend Yield | 1.27% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker Corporation (SYK) trades at $275.40, down 1.11% amid bearish technical signals and recent negative news regarding manufacturing issues. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $3.69 versus $3.49 expected, and profitability metrics remain robust with a 14.43% net income margin. Analyst consensus remains overwhelmingly bullish with a $368.11 price target representing 33% upside potential.
Despite near-term headwinds from manufacturing disclosures and legal investigations, Stryker's solid earnings track record, strong cash flow generation, and dominant medical technology position support long-term growth prospects. Key risks include ongoing legal scrutiny and competitive pressures in the medtech sector.
Wells Fargo (WFC) trades at $80.26, down 1.53% with a bearish technical signal. The stock shows strong fundamentals with revenue growth to $83.7B in 2025 and improving net margins to 25.49%. Recent positive developments include a credit rating upgrade to 'A-' by S&P and upcoming Q3 earnings. Valuation metrics appear attractive with P/E of 11.67 and P/B of 1.47, trading below the consensus price target of $99.13.
WFC presents a compelling value opportunity with solid profitability and analyst support (46.7% buy ratings), though near-term headwinds include recent earnings misses and bearish technical indicators. The bank's improving credit profile and stable outlook support long-term growth potential, but investors should monitor interest rate sensitivity and execution on earnings expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
